Navigation Links
CCNY professor gets grant to develop 'artificial blood'

As a post-doc at The University of Pennsylvania, Dr. Ron Koder, assistant professor of physics at The City College of New York, was part of a team that devised a novel method for producing an artificial protein capable of transporting oxygen, similar to human neuroglobin. He was recently awarded a three-year $1.3 million grant from the U.S. Department of Defense to develop an artificial blood that can be administered to injured troops on the battlefield.

"Engineered blood substitutes have a lot of attractive properties compared to blood drawn from people," he said. "No typing is required, you don't have to worry about refrigeration or freshness and there is no risk of infection." They can save lives, as well, since severely wounded servicemen and women sometimes die before they can be transported to a hospital and given a transfusion.

Professor Koder will use the grant to conduct laboratory studies to improve the stability and other properties of the protein. Then, he plans to cross-link the protein into large aggregates to create particles the same size as red blood cells.

Because the artificial hemoglobin binds oxygen in the presences of carbon monoxide, the substance also has the potential to prevent or treat carbon monoxide poisoning, he noted. However, this will not be part of the investigation.

Research like Professor Koder's investigation is part of the emerging field of biological design, a system for producing biological materials from scratch. Other potential applications include fighting AIDS and alternative energy. Biological design was the topic of a daylong symposium Friday, December 3, at the New York Academy of Sciences that Professor Koder helped organize.

"Natural materials are fussy. It's hard to get them to interact," he explained. "The (manmade) stuff is better for engineering more complex systems." Some of the biological design projects underway include developing metabolic pathways that could produce low-cost AIDS drugs, using solar energy to produce bio-fuels through artificial photosynthesis and making methanol from carbon dioxide.


Contact: Ellis Simon
City College of New York

Related biology news :

1. Rensselaer Polytechnic Institute professor Georges Belfort wins biochemical engineering award
2. UTHealth School of Biomedical Informatics professor to be inducted to AIMBE College of Fellows
3. ASU professor named top in state of Arizona
4. UH engineering professors featured in consecutive issues of Science
5. Falling in love more scientific than you think, according to Syracuse University professor
6. NJIT professor helps make case in Science for better biodiversity
7. 1 step closer to a drug treatment for cystic fibrosis, MU professor says
8. USDA awards grant to GSU professor to study childhood obesity dynamics
9. UD Professor Emeritus wins Nobel Prize in Chemistry
10. Louisiana Tech professor partners with local schools to study menu nutrition
11. Nobel Prize for Professor Robert G. Edwards, Editor Emeritus of Reproductive BioMedicine Online
Post Your Comments:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology: